SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " GLP-1 " 320 found 🔀 AI-powered Shuffle
The science of losing weight : Life Kit: Health
When it comes to weight loss, there are many misconceptions about what works. So if you want to lose weight this year, here's what the science says about the potential health benefits, GLP-1 drugs, exercise and more.Sign up for Life Kit's Guide to Building Strength here: npr.org/strongerFollow us on Instagram: @nprlifekitSign up for our newsletter here.Have an episode idea or feedback you want to share? Email us at lifekit@npr.orgSupport the show and listen to it sponsor-free by signing up for Life Kit+ at plus.npr.org/lifekit
The science of losing weight : Life Kit: Health
When it comes to weight loss, there are many misconceptions about what works. So if you want to lose weight this year, here's what the science says about the potential health benefits, GLP-1 drugs, exercise and more.Sign up for Life Kit's Guide to Building Strength here: npr.org/strongerFollow us on Instagram: @nprlifekitSign up for our newsletter here.Have an episode idea or feedback you want to share? Email us at lifekit@npr.orgSupport the show and listen to it sponsor-free by signing up for Life Kit+ at plus.npr.org/lifekit
The science of losing weight : Life Kit
When it comes to weight loss, there are many misconceptions about what works. So if you want to lose weight this year, here's what the science says about the potential health benefits, GLP-1 drugs, exercise and more.Sign up for Life Kit's Guide to Building Strength here: npr.org/strongerFollow us on Instagram: @nprlifekitSign up for our newsletter here.Have an episode idea or feedback you want to share? Email us at lifekit@npr.orgSupport the show and listen to it sponsor-free by signing up for Life Kit+ at plus.npr.org/lifekit
2026 Health Care Predictions: AI, GLP-1s, MAHA, DEI: Sachin H. Jain, MD, MBA
Sachin H. Jain, MD, MBA, discusses 2026 health care predictions, including AI adoption, GLP-1 demand, MAHA growth, DEI’s return, and policy shifts.
In 2026, Kennedy’s MAHA vision gets put to the test. Here are 3 issues to watch
In 2026, Robert F. Kennedy Jr.'s health policy changes will start playing out on GLP-1s, dietary guidelines, and rural health initiatives.
US health agency to negotiate prices for GLP-1 weight-loss drugs
The U.S. Centers for Medicare and Medicaid Services said on Tuesday it will negotiate drug prices with manufacturers of GLP-1 medications, in an attempt to expand access to the weight-loss treatments.
With FDA approval of Wegovy pill, new era of oral GLP-1 weight loss drugs begins
With FDA approval of Wegovy pill, new era of oral GLP-1 weight loss drugs begins
3 markers of health could help with weight-loss strategies, obesity expert reveals
Obesity medicine specialist Dr. Rocio Salas-Whalen, M.D., author of the new book "Weightless," shared that the best way to determine the suitability of a GLP-1 is through body composition testing.
These people lost their sense of taste. Are GLP-1s to blame?
GLP-1s mute sugar in our bodies. That's impacting our taste buds.
These new 2026 health care laws are taking effect in Pa., N.J. and Del.
Bills on diagnostic breast cancer testing, GLP-1 medications, lead paint and breastfeeding were signed into law.
GLP-1s may weaken the pelvic floor, impacting women's health –– and their sex lives
GLP-1 side effects like constipation and muscle mass loss can lead to uncomfortable pelvic floor symptoms like bladder leakage and painful sex.
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat (3.5 lbs; p=0.07), and a 3.2% increase in lean mass (4.0 lbs; p=0.01), with no statistically significant changes in the placebo group Sustained and robust suppression of serum Activin E supports expectations for continued improvements in body composition, further fat loss, and p
Driven by GLP-1s, prescription drug spending explodes at major health insurers
Some insurers have spent more on drugs in nine months this year than they did in all of 2024. Cost of weight loss drugs a major factor, STAT analysis finds.
Here’s What the World Health Organization Had to Say About GLP-1s in its First-Ever Guideline on the Drugs
The health agency supports the long-term use of the medications in combination with a healthy diet and exercise, and calls for equitable access to the drugs
World Health Organization issues guidelines for GLP-1 weight loss medication use
Fox News senior medical analyst Dr. Marc Siegel discusses the World Health Organization announcing its first guidelines on weight loss drugs, his book ‘The Miracles Among Us’ and its Fox Nation special on ‘America’s Newsroom.’
World Health Organization recommends GLP-1 drugs for obesity
The World Health Organization is now recommending GLP-1 drugs for adults trying to manage obesity. Dr. Natalie Azar explains how this historical shift changes the approach for patients.
WHO issues guidance on GLP-1 drugs for obesity, calls them a "scientific breakthrough" and "new chapter"
WHO issues global guideline on the use of GLP-1 medicines in treating obesity
To address the growing global health challenge of obesity, which affects more than 1 billion people, WHO has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease.
World Health Organization recommends GLP-1s for obesity. There's a catch.
The WHO issued guideline on the use of GLP-1 therapies for obesity, conditionally recommending them as part of long-term treatment.
WHO recommends GLP-1 drugs for obesity
The weight loss medications can be part of a long-term treatment strategy for adults, according to new World Health Organization guidelines.